血清半胱氨酸蛋白酶抑制剂C水平与脑梗死的关系及其影响因素的探讨
|
摘要
目的:观察脑梗死患者血清半胱氨酸蛋白酶抑制剂C(Cystatin C)的变化,并探讨其临床意义。目前很多研究认为半胱氨酸蛋白酶抑制剂C(Cystatin C)和脑血管发病有关,是阿尔茨海默病和脑出血的诱发因素,国外有研究认为Cystatin C是无症状性脑梗死发病的影响因素。临床脑梗死发病率和致残率都很高,本课题考察半胱氨酸蛋白酶抑制剂C(Cystatin C)与脑梗死的关系,评价Cystatin C在脑梗死病程病情方面应用价值,以便予以临床干预。
对象与方法:病历选择均为我院2007年1月～2007年10月期间住院患者84例,男46例,女38例;均符合临床脑梗死诊断标准,并经头颅CT或MRI证实。⑵对照组选自我院同期体检人群76人,男33例,女43例。采用面对面问卷及查阅病历调查形式由研究生本人填写调查表,收集调查对象的一般情况及相关信息。调查同时,搜集抽取健康对照者及住院患者清晨空腹静脉血液标本3ml,分离血清,-20℃冰箱保存,标本搜集完整后一起检测。
本实验由我院HIV-Ab实验室采用END POINT仪器,试剂由上海德波生物技术有限公司提供,采用酶联免疫法,酶标仪在490nm波长测定。
整理数据,输入计算机,用Excel 2003建库,SPSS(11.5)软件包进行统计分析。各组数据用均数±标准差表示,计量资料用t检验,计数资料用χ2检验或方差分析,对脑梗死与其它各个危险因素进行多因素Logistic回归分析,脑梗死与其它变量的关系用多元逐步回归分析。
结果:1.脑梗死组与正常对照组相比,脑梗死组血清半胱氨酸蛋白酶抑制剂C(1.69360±0.603101)mg/L明显低于正常对照组(2.00619±0.679114)mg/L,差异有统计学意义(P=0.002<0.05)。2.分层分析后发现,女性血清半胱氨酸蛋白酶抑制剂C水平稍高于男性,差异无统计学意义(P>0.05)。性别与血清半胱氨酸蛋白酶抑制剂C水平无明显相关(r=0.004),相关无有统计学意义(P=0.96>0.05)。3.血清半胱氨酸蛋白酶抑制剂C水平与年龄呈正相关性(r=0.206),相关有统计学意义(P=0.009<0.05)。4.血清半胱氨酸蛋白酶抑制剂C水平与CHOL、TG无相关性。5.血清半胱氨酸蛋白酶抑制剂C水平与胆红素呈负相关(Cystatin C与DBIL r=-0.168, P=0.034<0.05)。
结论:1.脑梗死的发病与半胱氨酸蛋白酶抑制剂C(Cystatin C)可能有关,半胱氨酸蛋白酶抑制剂C(Cystatin C)可能是脑梗死发病的影响因素。2.半胱氨酸蛋白酶抑制剂C(Cystatin C)水平与年龄相关,随年龄增长而升高。3.半胱氨酸蛋白酶抑制剂C(Cystatin C)水平与性别无关。4.血清半胱氨酸蛋白酶抑制剂C水平与CHOL、TG水平无关。5.血清半胱氨酸蛋白酶抑制剂C水平与胆红素呈负相关。
Objectives: to observe the changes of serum Cystatin C in patients with cerebral infarction and investigate its clinical significance. many researches considered Cystatin C was related with cerebrovascular disease, and it was a causative factor of Alzheimer disease and brain hemorrhage, some overseas researches considered Cystatin C was a protective factor to asymptomatic cerebral infarction. The disease rate and mutilation rate of clinical cerebral infarction are very high, the aim of this study is to investigate the relationship of Cystatin C and cerebral infarction, evaluate the application value of Cystatin C in condition and course of cerebral infarction, so as to give clinical intervention.
Objects and Methods: from January to October in 2007, 84 cerebral infarction in patients diagnosed through CT and (or) MRI were selected, include 46 male and 38 female cases, at the corresponding time period, 76 subjects accepted health examination were selected as control group, include 33 male and 43 female cases. To fill in questionnaires by the method of face to face questionnaire and look up the illness records, collected the general state of health and correlated information of all cases. At the same time, to draw blood 3ml from each person of the two groups, to separate serum, preserved in -20℃refrigerator and determine samples when collection was over. This experiment was carried out in HIV-Ab laboratory, used END POINT instrument, reagents were supplied by Shang-hai De-bo biology technology limited company, samples were determined by method of euzymelinked immunosorbent assay, wavelength was 490nm. To arrange the data and input in computer, establish table by Excel 2003, adopt package SPSS(11.5)to carry out statistical analysis. All data were indicated by mean±standard deviation, measurement data were analyzed by T test, numeration data were analyzed byχ2 test or F test, cerebral infarction and each risk factor were analyzed by multiple factor Logistic regression analysis, the relation of cerebral infarction and other variables were analyzed by multivariant gradual regressive analysis.
Result: 1. serum Cystatin C is significantly lower in cerebral infarction group(1.69360±0.603101) compared with control group(2.00619±0.679114), there was statistical significance between the two group(P=0.002<0.05). 2. the level of serum Cystatin C in female objects was higher than male objects, but there was no statistical significance between them(P>0.05).There was no associativity between gender and serum Cystatin C(r=0.004, P=0.96>0.05).3. There was positive correlation between age and serum Cystatin C(r=0.206, P=0.009<0.05).
Conclusion:1. Cystain C is possible related to cerebral infarction, Cystain C is a possible infuluential factor to clinical cerebral infarction. 2. There is a positive correlation between age and serum Cystatin C, the level of serum Cystatin C rises along with age. 3. There is no correlation between gender and Cystatin C.
对象与方法:病历选择均为我院2007年1月～2007年10月期间住院患者84例,男46例,女38例;均符合临床脑梗死诊断标准,并经头颅CT或MRI证实。⑵对照组选自我院同期体检人群76人,男33例,女43例。采用面对面问卷及查阅病历调查形式由研究生本人填写调查表,收集调查对象的一般情况及相关信息。调查同时,搜集抽取健康对照者及住院患者清晨空腹静脉血液标本3ml,分离血清,-20℃冰箱保存,标本搜集完整后一起检测。
本实验由我院HIV-Ab实验室采用END POINT仪器,试剂由上海德波生物技术有限公司提供,采用酶联免疫法,酶标仪在490nm波长测定。
整理数据,输入计算机,用Excel 2003建库,SPSS(11.5)软件包进行统计分析。各组数据用均数±标准差表示,计量资料用t检验,计数资料用χ2检验或方差分析,对脑梗死与其它各个危险因素进行多因素Logistic回归分析,脑梗死与其它变量的关系用多元逐步回归分析。
结果:1.脑梗死组与正常对照组相比,脑梗死组血清半胱氨酸蛋白酶抑制剂C(1.69360±0.603101)mg/L明显低于正常对照组(2.00619±0.679114)mg/L,差异有统计学意义(P=0.002<0.05)。2.分层分析后发现,女性血清半胱氨酸蛋白酶抑制剂C水平稍高于男性,差异无统计学意义(P>0.05)。性别与血清半胱氨酸蛋白酶抑制剂C水平无明显相关(r=0.004),相关无有统计学意义(P=0.96>0.05)。3.血清半胱氨酸蛋白酶抑制剂C水平与年龄呈正相关性(r=0.206),相关有统计学意义(P=0.009<0.05)。4.血清半胱氨酸蛋白酶抑制剂C水平与CHOL、TG无相关性。5.血清半胱氨酸蛋白酶抑制剂C水平与胆红素呈负相关(Cystatin C与DBIL r=-0.168, P=0.034<0.05)。
结论:1.脑梗死的发病与半胱氨酸蛋白酶抑制剂C(Cystatin C)可能有关,半胱氨酸蛋白酶抑制剂C(Cystatin C)可能是脑梗死发病的影响因素。2.半胱氨酸蛋白酶抑制剂C(Cystatin C)水平与年龄相关,随年龄增长而升高。3.半胱氨酸蛋白酶抑制剂C(Cystatin C)水平与性别无关。4.血清半胱氨酸蛋白酶抑制剂C水平与CHOL、TG水平无关。5.血清半胱氨酸蛋白酶抑制剂C水平与胆红素呈负相关。
Objectives: to observe the changes of serum Cystatin C in patients with cerebral infarction and investigate its clinical significance. many researches considered Cystatin C was related with cerebrovascular disease, and it was a causative factor of Alzheimer disease and brain hemorrhage, some overseas researches considered Cystatin C was a protective factor to asymptomatic cerebral infarction. The disease rate and mutilation rate of clinical cerebral infarction are very high, the aim of this study is to investigate the relationship of Cystatin C and cerebral infarction, evaluate the application value of Cystatin C in condition and course of cerebral infarction, so as to give clinical intervention.
Objects and Methods: from January to October in 2007, 84 cerebral infarction in patients diagnosed through CT and (or) MRI were selected, include 46 male and 38 female cases, at the corresponding time period, 76 subjects accepted health examination were selected as control group, include 33 male and 43 female cases. To fill in questionnaires by the method of face to face questionnaire and look up the illness records, collected the general state of health and correlated information of all cases. At the same time, to draw blood 3ml from each person of the two groups, to separate serum, preserved in -20℃refrigerator and determine samples when collection was over. This experiment was carried out in HIV-Ab laboratory, used END POINT instrument, reagents were supplied by Shang-hai De-bo biology technology limited company, samples were determined by method of euzymelinked immunosorbent assay, wavelength was 490nm. To arrange the data and input in computer, establish table by Excel 2003, adopt package SPSS(11.5)to carry out statistical analysis. All data were indicated by mean±standard deviation, measurement data were analyzed by T test, numeration data were analyzed byχ2 test or F test, cerebral infarction and each risk factor were analyzed by multiple factor Logistic regression analysis, the relation of cerebral infarction and other variables were analyzed by multivariant gradual regressive analysis.
Result: 1. serum Cystatin C is significantly lower in cerebral infarction group(1.69360±0.603101) compared with control group(2.00619±0.679114), there was statistical significance between the two group(P=0.002<0.05). 2. the level of serum Cystatin C in female objects was higher than male objects, but there was no statistical significance between them(P>0.05).There was no associativity between gender and serum Cystatin C(r=0.004, P=0.96>0.05).3. There was positive correlation between age and serum Cystatin C(r=0.206, P=0.009<0.05).
Conclusion:1. Cystain C is possible related to cerebral infarction, Cystain C is a possible infuluential factor to clinical cerebral infarction. 2. There is a positive correlation between age and serum Cystatin C, the level of serum Cystatin C rises along with age. 3. There is no correlation between gender and Cystatin C.
引文
1.杨期东,主编.神经病学,第一版,北京:人民卫生出版社,2002,130-137
2.Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W.Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007 Dec;72(12):1535-42
3.崔蒙,刘加芳,杨清萍,徐金英,刘建迪.高血压病患者血清半胱氨酸蛋白酶抑制剂C测定的临床意义.浙江医学, 2006,28(5):334-335
4.王文武,涂茹,丛蓉.血清Cystatin C作为肾功能标志物.微循环学杂志,2006 ,16(2) :39-41
5.杭宏东,王可平,林洪丽等.血清半胱氨酸蛋白酶抑制剂C在临床中的应用.中华现代临床医学杂志, 2004,2(3):214-216
6.Hademenos, G.J. PhD; Alberts, M.J. MD; et al . Advances in the genetics of cerebrovascular disease and stroke. ? 2001 American Academy of Neurology, 2001 April, 24;56(8): 997-1008
7.Remes, A M. MD, PhD; Finnil?, S MD, PhD;et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy.?2004AAN Enterprises, Inc. 2004 ,July27,63(2):234-240
8.Levy,-E; Sastre,-M; Kumar,-A; et al . Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J-Neuropathol-Exp-Neurol. 2001 Jan; 60(1): 94-104
9. Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
10.Tian,-J; Shi,-J; Mann,-D-M. Cerebral amyloid angiopathy and dementia. Panminerva-Med. 2004 Dec; 46(4): 253-64
11. Crawford, F. C. PhD; Freeman, M. J. BA; Schinka, J. A. et al . A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease . ? 2000 American Academy of Neurology .2000September26, 55(6): 763-768
12.Seliger,-S-L; Longstreth,-W-T Jr; Katz,-R;et al. Cystatin C and subclinical brain infarction. J-Am-Soc-Nephrol. 2005 Dec:16(12): 3721-7
13.陈菁,朱东芳. Cystatin C的检测及临床应用,绍兴文理学院学报. 2004,24(7),107-108
14.齐志宏.半胱氨酸蛋白酶抑制剂C的生物化学特性及其临床意义.北京医学,2002,24(2): 126-128
15. Fanos V , Mussap M , Plebani M ,et al. Cystatin C in paediatricnephrology. Present situation and prospects. Minerva Pediatr ,1999 ,51:167-177
16.Cataldi L ,Mussap M ,Bertelli L ,et al. Cystatin C in healthy womenat termpregnancy and in their infant newborns:relationship betweenmaternal and neonatal serum levels and reference values.Am J Peri- natol ,1999 ,16:287-295
17.钟巧、梅家平、杨传忠等,新生儿期血清Cystatin C动态变化的研究,中国小儿急救医学,2006 ,12 ,13[6]524-525
18.Odden MC, Chertow GM, Fried LF, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study.Am J Epidemiol. 2006 Dec ;164(12):1180-1189
19.Harmoinen A, Ylinen E,Ala-Houhala M et al.Reference intervals for cystatin C in pre- and full-term infants and children.Pediatr Nephrol. 2000 Nov;15(1-2):105-108
20.Bokenkamp A,Domanetzki M,Zinck R et al.Reference values for cystatin C serum concentrations in children. Pediatr Nephrol. 1998 Feb;12(2):125-129
21.Finney H,Newman DJ,Thakkar H et al.Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children.Arch Dis Child. 2000 Jan;82(1):71-75
22.Ognibene A, Mannucci E, Caldni A at al. Cystatin C reference valuesand aging.Clin Biochem. 2006 Jun;39(6):658-661
23.Sarnak MJ, Katz R, Fired LF et al.Cystatin C and aging success.Arch Intern Med. 2008 Jan 28;168(2):147-153
24.Seliger,-S-L; Longstreth,-W-T Jr; Katz,-R;et al. Cystatin C and subclinical brain infarction. J-Am-Soc-Nephrol. 2005 Dec; 16(12): 3721-3727
25.吕家高,倪黎,严江涛等.血浆胱氨酸蛋白酶抑制剂C水平与脑出血关系的病例对照研究.中华老年心脑血管病杂志.2006,9,8(9):610-612.
26. Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
27.Shlipak,-M-G; Sarnak,-M-J; Katz,-R; et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N-Engl-J-Med. 2005 May 19; 352(20): 2049-60
28.胡欣,徐岩,程自平等.冠心病患者血清半胱氨酸蛋白酶抑制剂C、同型半胱氨酸及肿瘤坏死因子a浓度的变化.临床荟萃.2006,7,21(3):939-940
29. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.Circulation. 2007 Jan 16;115(2):173-9
30. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events.Clin Chem, 2005 Feb;51(2):321-7
31. Bostom AG, Bausserman L, Jacques PF,et al. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine.Arterioscler Thromb Vasc Biol, 1999 Sep;19(9):2241-4
32.Erdogan D,Gullu H,Yildirim E,et al.Low serum bilirubin levels areindependently and inversely related to impaired flow-mediated vasodilatioand increased carotid intima-media thickness in both men and women .Atherosclerosis,2006 ,184(2) :431-437
33.蒋兴亮,周京国,唐中.脑梗死患者血浆胆红素和氧化低密度脂蛋白水平变化及意义.中华急诊医学杂志,2005 ,14(2) :157-160
34.SCHWERTNER HA,JACKSON WG,TOLAN G,et al. Association of low serum concentration of bilirubin with increased risk of coronarn artery disease. Clin Chem.1994,40(1):18-23
35.MAYER M. Association of serum bilirubin concentration with risk of coronarn artery disease. Clin Chem,2000,46(11):1723-1727
36.王钟秀、杨林花、刘秀娥等.脑梗死患者血清胆红素及血脂变化的临床意义探讨.血栓与止血学.2007,13(2):73-75
37.匡良洪.血胆红素、血尿酸及血脂与脑梗死关系分析.疑难病杂志,2006,4,5(2):129-130
38.李连瑛.临床诊断治疗技术.第1版.济南:济南出版社;2004:125-131
39.谢惠芳,田时雨.高血脂与脑血管疾病.新医学,2000 ,31(1) :14
40.翟岱安.血脂测定在脑梗死患者应用价值.实用医技杂志,2006,9,13 (17):3011-3012
41.叶任高、陆再英.内科学.第六版.北京:人民卫生出版社.2004:794
42.范存秀许祝青.2型糖尿病合并脑梗死临床研究.交通医学. 2007, 21(6):672-673
1.陈菁,朱东芳. Cystatin C的检测及临床应用,绍兴文理学院学报,2004,24(7),107-108
2.齐志宏.半胱氨酸蛋白酶抑制剂C的生物化学特性及其临床意义.北京医学,2002,24(2): 126-128
3.邱冬(综述),段勇,王玉明(审校). CystatinC的测定及临床意义.医学综述, 2005, 11(6) :544-547
4.Cataldi L ,Mussap M ,Bertelli L ,et al. Cystatin C in healthy womenat termpregnancy and in their infant newborns:relationship betweenmaternal and neonatal serum levels and reference values.Am J Peri2 natol ,1999 ,16:287-295
5. Fanos V , Mussap M , Plebani M ,et al. Cystatin C in paediatricnephrology. Present situation and prospects. Minerva Pediatr ,1999 ,51:167-177
6.Harmoinen A, Ylinen E,Ala-Houhala M et al.Reference intervals for cystatin C in pre- and full-term infants and children.Pediatr Nephrol. 2000 Nov;15(1-2):105-108
7.Bokenkamp A,Domanetzki M,Zinck R et al.Reference values for cystatin C serum concentrations in children. Pediatr Nephrol. 1998 Feb;12(2):125-129
8.Finney H,Newman DJ,Thakkar H et al.Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children.Arch Dis Child. 2000 Jan;82(1):71-75
9.Ognibene A, Mannucci E, Caldni A at al. Cystatin C reference values and aging.Clin Biochem. 2006 Jun;39(6):658-661
10.Sarnak MJ, Katz R, Fired LF,et al.Cystatin C and aging success.Arch Intern Med. 2008 Jan 28;168(2):147-153
11.崔蒙,刘加芳,杨清萍,等.高血压病患者血清半胱氨酸蛋白酶抑制剂C测定的临床意义.浙江医学, 2006,28(5):334-335
12.王文武,涂茹,丛蓉.血清Cystatin C作为肾功能标志物.微循环学杂志,2006 ,16(2) :39-41
13.杭宏东,王可平,林洪丽等.血清半胱氨酸蛋白酶抑制剂C在临床中的应用.中华现代临床医学杂志, 2004,2(3):214-216
14.Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W.Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007 Dec;72(12):1535-42
15.李朝霞,黄美莲,梁敏坚,陈忠成.半胱氨酸蛋白酶抑制剂C-一种新的儿童肾小球滤过率的内源性标志物.右江医学, 2002,30(4):321-323
16.谢媛,李智,许丙根等.血清CysC与尿微量蛋白在肾脏疾病诊断中的意义.世界感染杂志, 2005,5(3):216-218
17.Risch L ,Blumberg A,Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants usingserum cystatin C.Nephrol Dial Transplant ,1999 ,14:1991-1996
18.Le Bricon T, Thervet E, Benlakehal M, Bousquet B , Legendre C, Er
2lich D. Changes in plasma cystatin Cafter renal transplantation and acute rejection in adults. Clin Chem ,1999,45(2):2243
19.Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, Shlipak MG .Cystatin C level as a marker of kidney function in human immunodeficiency virus infection. the FRAM study. Arch Intern Med, 2007 Nov 12,167(20):2213-2219
20.郑淑蓓,季亢挺,周野,等.冠心病患者检测血清半胱氨酸蛋白酶抑制剂C的意义.浙江实用医学,2007,8 ,12 (4 ):236-237
21.胡欣,徐岩,程自平等.冠心病患者血清半胱氨酸蛋白酶抑制剂C、同型半胱氨酸及肿瘤坏死因子α浓度的变化.临床荟萃,2006,21 (13):939
22. Yetkin E, Acikgoz N, Sivri N et al. Increased plasma levels of cystatin C and transforming growth factor-beta1 in patients with coronary artery ectasia: can there be a potential interaction between cystatin C and transforming growth factor-beta1.Coron Artery Dis, 2007 May,18(3):211-214
23. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.Circulation. 2007 Jan 16;115(2):173-9
24. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events.Clin Chem, 2005 Feb;51(2):321-7
25. Bostom AG, Bausserman L, Jacques PF,et al. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine.Arterioscler Thromb Vasc Biol, 1999 Sep;19(9):2241-4
26.Shlipak,-M-G; Sarnak,-M-J; Katz,-R; et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N-Engl-J-Med. 2005 May 19; 352(20): 2049-60
27.Eriksson,-P; Deguchi,-H; Samnegard,-A et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler-Thromb-Vasc-Biol. 2004 Mar; 24(3): 551-7
28.Jernberg,-T; Lindahl,-B; James,-S; et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004 Oct 19; 110(16): 2342-8
29. Crawford, F. C. PhD; Freeman, M. J. BA; Schinka, J. A. et al . A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease . ? 2000 American Academy of Neurology .2000 September26, 55(6): 763-768
30.Hademenos, G.J. PhD; Alberts, M.J. MD; et al . Advances in the genetics of cerebrovascular disease and stroke. ? 2001 American Academy of Neurology, 2001 April, 24;56(8): 997-1008
31.Remes, A M. MD, PhD; Finnil?, S MD, PhD;et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy.?2004AAN Enterprises, Inc. 2004 ,July27,63(2):234-240
32.Levy,-E; Sastre,-M; Kumar,-A; et al . Codeposition of cystatin C withamyloid-beta protein in the brain of Alzheimer disease patients. J-Neuropathol-Exp-Neurol. 2001 Jan; 60(1): 94-104
33.Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
34.吕家高,倪黎,严江涛等.血浆胱氨酸蛋白酶抑制剂C水平与脑出血关系的病例对照研究.中华老年心脑血管病杂志,2006,9, 8 (9):610-612
35.lker,-L-C; Durham,-R-A. Cerebrovascular amyloidosis: experimental analysis in vitro and in vivo. Histol-Histopathol. 1999 Jul; 14(3): 827-37
36.Pirttila,-T-J; Pitkanen,-A.Cystatin C expression is increased in the hippocampus following photo thrombotic stroke in rat. Neurosci-Lett. 2006 Mar 6; 395(2): 108-13
37.Tian,-J; Shi,-J; Mann,-D-M. Cerebral amyloid angiopathy and dementia. Panminerva-Med. 2004 Dec; 46(4): 253-64
38.Catheart H.M. Huang R. Lanham I.S. et al. Cystatin C as a risk factor for Alzheimer disease.Clinical Neurology.2005 8;1(8):51-52
39.Frangione,-B; Revesz,-T; Vidal,-R; et al. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid. 2001 Jul; 8 (1): 36-42.
40.Levy,-E; Jaskolski,-M; Grubb,-A.The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain-Pathol. 2006 Jan; 16(1): 60-70
41.韩瑞刚.阿尔茨海默病相关基因研究进展.国外医学·老年医学分册, 2002,23(2): 55-57
42.马荣红,温小波,崔天盆,吴健民.脑转移瘤患者脑脊液半胱氨酸蛋白酶抑制剂C变化的临床意义.临床检验杂志,2004,22(5):375-376
43.陈军政.2型糖尿病肾病患者血清胱抑素C的检测及意义.微循环学杂志,2007,17(3):58-59
44.陆卫平,张妮娅,姜玉章等.2型糖尿病患者血清Cystatin C的表达及其意义.临床医学,2007,62(181):56-57
45.邱谷,黄桥林,陈红梅等.CystatinC和NAG测定在糖尿病肾损害诊断中的作用.检验医学与临床,2007,4(3):180-181
46.赵瑛瑛,欧阳军,王建生,田晨光等.半胱氨酸蛋白酶抑制剂C在糖尿病肾病中的诊断价值.中原医刊,2007,34(16):27-28
47.邱谷,黄桥林,陈红梅,等.健康人群血清CystatinC参考值调查及其对糖尿病肾损害诊断的作用,现代检验医学杂志,2007,22(4):94-95
48.黄群,杨香玖,姚弘,张岩,黄延玲等.血清胱抑素在2型糖尿病不同肾损害期的变化及其临床意义,临床内科杂志,2006,23(7):476-477
49.Peczyńska J, Urban M, G?owińska B, Florys B. If the level of cystatin C in children and adolescents with type 1 diabetes an early marker for diabetic nephropathy,Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005;11(3):141-6
50.Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients.Clin Chem. 2007 Mar;53(3):480-8
2.Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W.Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007 Dec;72(12):1535-42
3.崔蒙,刘加芳,杨清萍,徐金英,刘建迪.高血压病患者血清半胱氨酸蛋白酶抑制剂C测定的临床意义.浙江医学, 2006,28(5):334-335
4.王文武,涂茹,丛蓉.血清Cystatin C作为肾功能标志物.微循环学杂志,2006 ,16(2) :39-41
5.杭宏东,王可平,林洪丽等.血清半胱氨酸蛋白酶抑制剂C在临床中的应用.中华现代临床医学杂志, 2004,2(3):214-216
6.Hademenos, G.J. PhD; Alberts, M.J. MD; et al . Advances in the genetics of cerebrovascular disease and stroke. ? 2001 American Academy of Neurology, 2001 April, 24;56(8): 997-1008
7.Remes, A M. MD, PhD; Finnil?, S MD, PhD;et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy.?2004AAN Enterprises, Inc. 2004 ,July27,63(2):234-240
8.Levy,-E; Sastre,-M; Kumar,-A; et al . Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J-Neuropathol-Exp-Neurol. 2001 Jan; 60(1): 94-104
9. Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
10.Tian,-J; Shi,-J; Mann,-D-M. Cerebral amyloid angiopathy and dementia. Panminerva-Med. 2004 Dec; 46(4): 253-64
11. Crawford, F. C. PhD; Freeman, M. J. BA; Schinka, J. A. et al . A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease . ? 2000 American Academy of Neurology .2000September26, 55(6): 763-768
12.Seliger,-S-L; Longstreth,-W-T Jr; Katz,-R;et al. Cystatin C and subclinical brain infarction. J-Am-Soc-Nephrol. 2005 Dec:16(12): 3721-7
13.陈菁,朱东芳. Cystatin C的检测及临床应用,绍兴文理学院学报. 2004,24(7),107-108
14.齐志宏.半胱氨酸蛋白酶抑制剂C的生物化学特性及其临床意义.北京医学,2002,24(2): 126-128
15. Fanos V , Mussap M , Plebani M ,et al. Cystatin C in paediatricnephrology. Present situation and prospects. Minerva Pediatr ,1999 ,51:167-177
16.Cataldi L ,Mussap M ,Bertelli L ,et al. Cystatin C in healthy womenat termpregnancy and in their infant newborns:relationship betweenmaternal and neonatal serum levels and reference values.Am J Peri- natol ,1999 ,16:287-295
17.钟巧、梅家平、杨传忠等,新生儿期血清Cystatin C动态变化的研究,中国小儿急救医学,2006 ,12 ,13[6]524-525
18.Odden MC, Chertow GM, Fried LF, et al. Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study.Am J Epidemiol. 2006 Dec ;164(12):1180-1189
19.Harmoinen A, Ylinen E,Ala-Houhala M et al.Reference intervals for cystatin C in pre- and full-term infants and children.Pediatr Nephrol. 2000 Nov;15(1-2):105-108
20.Bokenkamp A,Domanetzki M,Zinck R et al.Reference values for cystatin C serum concentrations in children. Pediatr Nephrol. 1998 Feb;12(2):125-129
21.Finney H,Newman DJ,Thakkar H et al.Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children.Arch Dis Child. 2000 Jan;82(1):71-75
22.Ognibene A, Mannucci E, Caldni A at al. Cystatin C reference valuesand aging.Clin Biochem. 2006 Jun;39(6):658-661
23.Sarnak MJ, Katz R, Fired LF et al.Cystatin C and aging success.Arch Intern Med. 2008 Jan 28;168(2):147-153
24.Seliger,-S-L; Longstreth,-W-T Jr; Katz,-R;et al. Cystatin C and subclinical brain infarction. J-Am-Soc-Nephrol. 2005 Dec; 16(12): 3721-3727
25.吕家高,倪黎,严江涛等.血浆胱氨酸蛋白酶抑制剂C水平与脑出血关系的病例对照研究.中华老年心脑血管病杂志.2006,9,8(9):610-612.
26. Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
27.Shlipak,-M-G; Sarnak,-M-J; Katz,-R; et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N-Engl-J-Med. 2005 May 19; 352(20): 2049-60
28.胡欣,徐岩,程自平等.冠心病患者血清半胱氨酸蛋白酶抑制剂C、同型半胱氨酸及肿瘤坏死因子a浓度的变化.临床荟萃.2006,7,21(3):939-940
29. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.Circulation. 2007 Jan 16;115(2):173-9
30. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events.Clin Chem, 2005 Feb;51(2):321-7
31. Bostom AG, Bausserman L, Jacques PF,et al. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine.Arterioscler Thromb Vasc Biol, 1999 Sep;19(9):2241-4
32.Erdogan D,Gullu H,Yildirim E,et al.Low serum bilirubin levels areindependently and inversely related to impaired flow-mediated vasodilatioand increased carotid intima-media thickness in both men and women .Atherosclerosis,2006 ,184(2) :431-437
33.蒋兴亮,周京国,唐中.脑梗死患者血浆胆红素和氧化低密度脂蛋白水平变化及意义.中华急诊医学杂志,2005 ,14(2) :157-160
34.SCHWERTNER HA,JACKSON WG,TOLAN G,et al. Association of low serum concentration of bilirubin with increased risk of coronarn artery disease. Clin Chem.1994,40(1):18-23
35.MAYER M. Association of serum bilirubin concentration with risk of coronarn artery disease. Clin Chem,2000,46(11):1723-1727
36.王钟秀、杨林花、刘秀娥等.脑梗死患者血清胆红素及血脂变化的临床意义探讨.血栓与止血学.2007,13(2):73-75
37.匡良洪.血胆红素、血尿酸及血脂与脑梗死关系分析.疑难病杂志,2006,4,5(2):129-130
38.李连瑛.临床诊断治疗技术.第1版.济南:济南出版社;2004:125-131
39.谢惠芳,田时雨.高血脂与脑血管疾病.新医学,2000 ,31(1) :14
40.翟岱安.血脂测定在脑梗死患者应用价值.实用医技杂志,2006,9,13 (17):3011-3012
41.叶任高、陆再英.内科学.第六版.北京:人民卫生出版社.2004:794
42.范存秀许祝青.2型糖尿病合并脑梗死临床研究.交通医学. 2007, 21(6):672-673
1.陈菁,朱东芳. Cystatin C的检测及临床应用,绍兴文理学院学报,2004,24(7),107-108
2.齐志宏.半胱氨酸蛋白酶抑制剂C的生物化学特性及其临床意义.北京医学,2002,24(2): 126-128
3.邱冬(综述),段勇,王玉明(审校). CystatinC的测定及临床意义.医学综述, 2005, 11(6) :544-547
4.Cataldi L ,Mussap M ,Bertelli L ,et al. Cystatin C in healthy womenat termpregnancy and in their infant newborns:relationship betweenmaternal and neonatal serum levels and reference values.Am J Peri2 natol ,1999 ,16:287-295
5. Fanos V , Mussap M , Plebani M ,et al. Cystatin C in paediatricnephrology. Present situation and prospects. Minerva Pediatr ,1999 ,51:167-177
6.Harmoinen A, Ylinen E,Ala-Houhala M et al.Reference intervals for cystatin C in pre- and full-term infants and children.Pediatr Nephrol. 2000 Nov;15(1-2):105-108
7.Bokenkamp A,Domanetzki M,Zinck R et al.Reference values for cystatin C serum concentrations in children. Pediatr Nephrol. 1998 Feb;12(2):125-129
8.Finney H,Newman DJ,Thakkar H et al.Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children.Arch Dis Child. 2000 Jan;82(1):71-75
9.Ognibene A, Mannucci E, Caldni A at al. Cystatin C reference values and aging.Clin Biochem. 2006 Jun;39(6):658-661
10.Sarnak MJ, Katz R, Fired LF,et al.Cystatin C and aging success.Arch Intern Med. 2008 Jan 28;168(2):147-153
11.崔蒙,刘加芳,杨清萍,等.高血压病患者血清半胱氨酸蛋白酶抑制剂C测定的临床意义.浙江医学, 2006,28(5):334-335
12.王文武,涂茹,丛蓉.血清Cystatin C作为肾功能标志物.微循环学杂志,2006 ,16(2) :39-41
13.杭宏东,王可平,林洪丽等.血清半胱氨酸蛋白酶抑制剂C在临床中的应用.中华现代临床医学杂志, 2004,2(3):214-216
14.Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W.Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007 Dec;72(12):1535-42
15.李朝霞,黄美莲,梁敏坚,陈忠成.半胱氨酸蛋白酶抑制剂C-一种新的儿童肾小球滤过率的内源性标志物.右江医学, 2002,30(4):321-323
16.谢媛,李智,许丙根等.血清CysC与尿微量蛋白在肾脏疾病诊断中的意义.世界感染杂志, 2005,5(3):216-218
17.Risch L ,Blumberg A,Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants usingserum cystatin C.Nephrol Dial Transplant ,1999 ,14:1991-1996
18.Le Bricon T, Thervet E, Benlakehal M, Bousquet B , Legendre C, Er
2lich D. Changes in plasma cystatin Cafter renal transplantation and acute rejection in adults. Clin Chem ,1999,45(2):2243
19.Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, Shlipak MG .Cystatin C level as a marker of kidney function in human immunodeficiency virus infection. the FRAM study. Arch Intern Med, 2007 Nov 12,167(20):2213-2219
20.郑淑蓓,季亢挺,周野,等.冠心病患者检测血清半胱氨酸蛋白酶抑制剂C的意义.浙江实用医学,2007,8 ,12 (4 ):236-237
21.胡欣,徐岩,程自平等.冠心病患者血清半胱氨酸蛋白酶抑制剂C、同型半胱氨酸及肿瘤坏死因子α浓度的变化.临床荟萃,2006,21 (13):939
22. Yetkin E, Acikgoz N, Sivri N et al. Increased plasma levels of cystatin C and transforming growth factor-beta1 in patients with coronary artery ectasia: can there be a potential interaction between cystatin C and transforming growth factor-beta1.Coron Artery Dis, 2007 May,18(3):211-214
23. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.Circulation. 2007 Jan 16;115(2):173-9
24. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events.Clin Chem, 2005 Feb;51(2):321-7
25. Bostom AG, Bausserman L, Jacques PF,et al. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine.Arterioscler Thromb Vasc Biol, 1999 Sep;19(9):2241-4
26.Shlipak,-M-G; Sarnak,-M-J; Katz,-R; et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N-Engl-J-Med. 2005 May 19; 352(20): 2049-60
27.Eriksson,-P; Deguchi,-H; Samnegard,-A et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler-Thromb-Vasc-Biol. 2004 Mar; 24(3): 551-7
28.Jernberg,-T; Lindahl,-B; James,-S; et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004 Oct 19; 110(16): 2342-8
29. Crawford, F. C. PhD; Freeman, M. J. BA; Schinka, J. A. et al . A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease . ? 2000 American Academy of Neurology .2000 September26, 55(6): 763-768
30.Hademenos, G.J. PhD; Alberts, M.J. MD; et al . Advances in the genetics of cerebrovascular disease and stroke. ? 2001 American Academy of Neurology, 2001 April, 24;56(8): 997-1008
31.Remes, A M. MD, PhD; Finnil?, S MD, PhD;et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy.?2004AAN Enterprises, Inc. 2004 ,July27,63(2):234-240
32.Levy,-E; Sastre,-M; Kumar,-A; et al . Codeposition of cystatin C withamyloid-beta protein in the brain of Alzheimer disease patients. J-Neuropathol-Exp-Neurol. 2001 Jan; 60(1): 94-104
33.Calero,-M; Pawlik,-M; Soto,-C;et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J-Neurochem. 2001 Apr; 77(2): 628-37
34.吕家高,倪黎,严江涛等.血浆胱氨酸蛋白酶抑制剂C水平与脑出血关系的病例对照研究.中华老年心脑血管病杂志,2006,9, 8 (9):610-612
35.lker,-L-C; Durham,-R-A. Cerebrovascular amyloidosis: experimental analysis in vitro and in vivo. Histol-Histopathol. 1999 Jul; 14(3): 827-37
36.Pirttila,-T-J; Pitkanen,-A.Cystatin C expression is increased in the hippocampus following photo thrombotic stroke in rat. Neurosci-Lett. 2006 Mar 6; 395(2): 108-13
37.Tian,-J; Shi,-J; Mann,-D-M. Cerebral amyloid angiopathy and dementia. Panminerva-Med. 2004 Dec; 46(4): 253-64
38.Catheart H.M. Huang R. Lanham I.S. et al. Cystatin C as a risk factor for Alzheimer disease.Clinical Neurology.2005 8;1(8):51-52
39.Frangione,-B; Revesz,-T; Vidal,-R; et al. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid. 2001 Jul; 8 (1): 36-42.
40.Levy,-E; Jaskolski,-M; Grubb,-A.The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain-Pathol. 2006 Jan; 16(1): 60-70
41.韩瑞刚.阿尔茨海默病相关基因研究进展.国外医学·老年医学分册, 2002,23(2): 55-57
42.马荣红,温小波,崔天盆,吴健民.脑转移瘤患者脑脊液半胱氨酸蛋白酶抑制剂C变化的临床意义.临床检验杂志,2004,22(5):375-376
43.陈军政.2型糖尿病肾病患者血清胱抑素C的检测及意义.微循环学杂志,2007,17(3):58-59
44.陆卫平,张妮娅,姜玉章等.2型糖尿病患者血清Cystatin C的表达及其意义.临床医学,2007,62(181):56-57
45.邱谷,黄桥林,陈红梅等.CystatinC和NAG测定在糖尿病肾损害诊断中的作用.检验医学与临床,2007,4(3):180-181
46.赵瑛瑛,欧阳军,王建生,田晨光等.半胱氨酸蛋白酶抑制剂C在糖尿病肾病中的诊断价值.中原医刊,2007,34(16):27-28
47.邱谷,黄桥林,陈红梅,等.健康人群血清CystatinC参考值调查及其对糖尿病肾损害诊断的作用,现代检验医学杂志,2007,22(4):94-95
48.黄群,杨香玖,姚弘,张岩,黄延玲等.血清胱抑素在2型糖尿病不同肾损害期的变化及其临床意义,临床内科杂志,2006,23(7):476-477
49.Peczyńska J, Urban M, G?owińska B, Florys B. If the level of cystatin C in children and adolescents with type 1 diabetes an early marker for diabetic nephropathy,Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005;11(3):141-6
50.Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients.Clin Chem. 2007 Mar;53(3):480-8